A large-scale cell culture method of malignant pleural and peritoneal effusion tumor-associated lymphocytes
By culturing lymphocytes from malignant pleural and peritoneal fluid using metabolic reprogramming technology, the problem of difficult tumor tissue extraction has been solved, and CD8+ T cells have been efficiently expanded, exhibiting strong tumor-specific killing ability, which is suitable for the treatment of solid tumors.
Patent Information
- Application Number
- CN202510735424.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-03
- Publication Date
- 2025-11-25
- Estimated Expiration
- 2045-06-03
AI Technical Summary
Existing technologies for extracting tumor-associated lymphoid tissues (TILs) from tumor tissues face challenges such as high technical difficulty, limited cell quantity, difficulty in expansion, poor selectivity of effector CD8+ lymphocytes, and insufficient chemotactic capacity of tumor lesions, resulting in poor efficacy of tumor immunotherapy.
Using metabolic reprogramming technology, lymphocytes were isolated and cultured from malignant pleural and peritoneal effusions of cancer patients. They were cultured in a medium containing IL-2, lymphoblast activator factor, and inactivated fetal bovine serum, and then further expanded in a WAVE bioreactor to activate the mitochondrial biosynthetic capacity of lymphocytes, enhance oxidative phosphorylation metabolism, and increase tissue infiltration.
Within 14-16 days, lymphocytes can be expanded 1000-fold to obtain highly cytotoxic CD8+ T cells, with a number reaching the order of 10¹⁰-10¹¹ and a cell viability of over 90%. These cells have a strong tumor-specific killing effect and are suitable for the treatment of solid tumors.